Cyclofenil is a selective estrogen receptor modulator and an ovulation-inducing agent. Cyclofenil shows an inhibitory effect on dengue virus replication in Vero cells with an EC50 of 1.62 μM. Cyclofenil has anti-dengue-virus activity.

Product information

CAS Number: 2624-43-3

Molecular Weight: 364.43

Formula: C23H24O4

Chemical Name: 4-{[4-(acetyloxy)phenyl](cyclohexylidene)methyl}phenyl acetate

Smiles: CC(=O)OC1C=CC(=CC=1)C(C1C=CC(=CC=1)OC(C)=O)=C1CCCCC1

InChiKey: GVOUFPWUYJWQSK-UHFFFAOYSA-N

InChi: InChI=1S/C23H24O4/c1-16(24)26-21-12-8-19(9-13-21)23(18-6-4-3-5-7-18)20-10-14-22(15-11-20)27-17(2)25/h8-15H,3-7H2,1-2H3

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 100 mg/mL (274.39 mM; Need ultrasonic).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Cyclofenil shows an inhibitory effect on dengue virus (DENV) replication in mammalian cells but not in mosquito cells. Cyclofenil also inhibits the replication of Zika virus. A time-of-addition assay suggested that Cyclofenil may interfere with two stages of the Dengue virus (DENV) life cycle: the translation-RNA synthesis and assembly-maturation stages. The level of intracellular infectious particles decreased more drastically after treatment with Cyclofenil than the viral RNA level do, indicating that the assembly-maturation stage might be the main target of Cyclofenil.

In Vivo:

The number of estrogen receptors α (ERα) and β (ERβ)-immunoreactive (-ir) cells is determined of each stage of the estrous cycle in intact rats. Additionally, the effects of blocking ERα and ERβ on ovulation rate on diestrus-2 or proestrus day through the microinjection of methyl-piperidino-pyrazole (MPP) or Cyclofenil in either side of preoptic-anterior hypothalamic area (POA-AHA) are evaluated. The number of ERα-ir and ERβ-ir cells in POA-AHA varied in each phase of estrous cycle. Either MPP or Cyclofenil in the right side of POA-AHA on diestrus-2 day reduced the ovulation rate, while at proestrus day it was decreased in rats treated in either side with MPP, and in those treated with Cyclofenil in the left side. MPP or Cyclofenil produced a decrease in the surge of luteinizing hormone levels (LH) and an increase in progesterone and follicle stimulating hormone (FSH).

Products are for research use only. Not for human use.